Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

LIQUID (BLOOD-BASED) BIOPSY to Determine Recurrence Risk and Chemotherapy Need in Colon-Rectal Cancer

LIQUID (BLOOD-BASED) BIOPSY to Determine Recurrence Risk and Chemotherapy Need in Colon-Rectal Cancer

With 1.3 million new cases each year, colorectal (large bowel) cancersare the 3rd most common cancer worldwide and the 2nd leading cause of cancer death. US statistics show that approximately 75% of patients with colorectal cancer are diagnosed at early or locally advanced stages (1 - 3), and 25% at the metastatic (4) stage. Despite advances in both early diagnosis and treatment, the 5-year survival rate for colorectal cancers is around 65%. New strategies are therefore needed in managing colon and rectal cancers.

One current standard treatment for locally advanced (stage 2 and 3) large bowel cancer involves surgical removal of the tumor, followed in some patients by adjuvant chemotherapy to destroy any remaining tumor cells. As standard, most stage 2 large bowel cancers arenotgiven this treatment. However, 10-15% of these patients are observed to have residual disease (remaining tumor tissue). Conversely, although complete tumor clearance can be achieved by surgery in stage 3 large bowel cancers in 50% of cases, most of these patients also receive adjuvant chemotherapy to reduce the risk of cancer recurrence (relapse) . Furthermore, in patients with stage 3 large bowel cancer receiving adjuvant chemotherapy, 30% are observed to experience recurrence later despite this treatment. Adjuvant chemotherapy therefore unintentionally plays a leading role in undertreatment of some patients and unnecessary overtreatment of others. To identify patients who will benefit from adjuvant treatment, better biomarkers are needed to identify those at high risk of recurrence. This would enable early detection of recurrence and identification of patients benefiting from adjuvant treatment, allowing follow-up and treatment strategies to be determined. At precisely this point, circulating tumor cell DNA in blood (ctDNA)emerges as a promising, noninvasive biomarker.

Research in recent years discovered that dying cancer cells release DNA fragments into the blood. These have been called circulating tumor DNA fragments (circulating tumor DNA =ctDNA). Methods of collecting and examining these tumor DNA fragments circulating in blood are generally called liquid (fluid, blood-based) biopsy . These methods involve working only with a small blood sample from the patient, without an invasive procedure. Recently, the role of liquid biopsies in predicting cancer recurrence has frequently been examined. In JAMA Oncology , a comprehensive study involving 122 patients addressed this issue.

In the study, blood samples were collected from patients with stage 1-2-3 large bowel cancer, numbering 122, before surgery, on postoperative day 30, and every 3 months for a total of 3 years. Circulating tumor DNA fragments (ctDNA) were examined in these samples.

Striking results

The study found that early postoperative ctDNA analyses, among 16 recurrences, identified 14. In samples obtained on postoperative day 30, those testing positive for ctDNA, compared with those testing negative, had 7 times more recurrences . Similarly, following adjuvant treatment, those testing positive for ctDNA, compared with those testing negative, had 17 times more recurrences . Indeed, all 7 patients testing positive for ctDNA after adjuvant treatment developed recurrence. Over the entire postoperative observation period, those testing positive for ctDNA, compared with those testing negative, had 40 times more recurrences in the study.

In conclusion; postoperative circulating tumor DNA analyses in patients with large bowel cancer helped detect recurrence early and evaluate adjuvant chemotherapy effectiveness. This technique may be used after surgery for large bowel cancer to select suitable patients for adjuvant chemotherapy, determine its duration and the observation period, and detect recurrence early. Circulating tumor DNA analyses may therefore change postoperative management of large bowel cancers. 

Sources

Reinert T, Henriksen TV et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 9 May 2019

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

LIQUID (BLOOD-BASED) BIOPSY to Determine Recurrence Risk and Chemotherapy Need in Colon-Rectal Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy